WilmerHale Advises Exo Therapeutics in $25 Million Series A Financing

WilmerHale Advises Exo Therapeutics in $25 Million Series A Financing

Client News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

On December 16, 2020, Exo Therapeutics, Inc., a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets, announced the completion of a $25 million Series A financing. Investors in the round included Newpath Partners, Novartis Venture Fund, CRV and 6 Dimensions Capital. Proceeds from the financing will be used to advance therapeutic candidates derived from the company’s ExoSight™ platform. Exo Therapeutics is advancing an initial portfolio of programs that are focused on oncology and inflammation by modulating enzyme activity in pathways where exosites are prevalent.

The WilmerHale team representing Exo Therapeutics was led by Jason Kropp and included Erin Garrity.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel